NORD supports policies that reduce patient out-of-pocket expenses to enable better access to the therapies rare disease patients need.
Innovative new treatments and scientific advancements are allowing many patients with rare diseases to live longer, healthier lives. Unfortunately, the cost of these medicines and other treatments can be prohibitive. NORD recognizes that the high cost of drugs has a direct impact on patient access and advocates for policies to lower patient out-of-pocket expenses and maximize access to needed therapies.
Trends in Out-of-Pocket Spending and Regulation
A patient’s out-of-pocket costs include their expenses for medical care that are not reimbursed by their insurance. This includes the:
For many rare disease patients, their out-of-pocket costs have grown significantly in recent years, as insurance companies are increasingly shifting the cost of health care onto patients by raising deductibles,1 increasing patient cost-sharing,2 and changing plan design.3 These actions can have grave consequences. Exorbitant out-of-pocket costs can force patients to go without their medication or to use alternative treatments that are not as safe and effective. For example, according to the Kaiser Family Foundation, 26% of all adults report difficulty affording their prescription drugs. Of those who were unable to afford their drugs, three in ten say they have not taken their medicine as prescribed due to cost.4
In recent years, there has been a push in state legislatures to assist patients with increasingly high prescription drug out-of-pocket costs, and states have explored different types of legislation with varying impacts on patients’ out-of-pocket spending. It is important to note that state lawmakers do not have authority over all forms of health insurance. Additionally, in August 2022, President Biden signed into law the Inflation Reduction Act, which will limit the out-of-pocket prescription drug costs for Medicare Part D beneficiaries to $2000 annually, but that will not begin until 2025 and is only applicable to Medicare beneficiaries who participate in the Part D program.5
For the purposes of this report, the analysis of out-of-pocket cost protections focuses solely on state-regulated health insurance plans.
Grading Methodology
NORD evaluated state out-of-pocket patient protections on the following:
The greater the number of protections states have enacted from above, the higher their grade.
Click to enlarge
By continuing to use this website, you agree to the Terms of Service & Privacy Policy